Cytogen Corporation Announces Schedule For Clinical Data Presentations At Upcoming American Society of Clinical Oncology, SNM, And EHA Meetings
PRINCETON, N.J., May 25 /PRNewswire-FirstCall/ -- Cytogen Corporation today announced that data from clinical studies related to the company's marketed products QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R) (capromab pendetide) will be presented at upcoming major medical conferences, including the 42nd American Society of Clinical Oncology (ASCO) annual meeting June 2-6 in Atlanta, Georgia, the 53rd Society of Nuclear Medicine (SNM) annual meeting June 3-7 in San Diego, California, and the 11th Congress of the European Hematology Association (EHA) held June 15-18 in Amsterdam, The Netherlands.
The following QUADRAMET abstracts will be presented at the ASCO annual meeting:
-- "Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma" will be presented on Saturday, June 3 from 8:00 a.m. to 12:00 p.m. during a Poster Session on Lymphoma and Plasma Cell Disorders (Abstract # 7614). -- "A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine" will be presented on Sunday, June 4 from 2:00 p.m. to 6:00 p.m. during a Poster Session on Genitourinary Cancer (Abstract # 4608).
For more information about the ASCO annual meeting, please refer to the conference website at http://www.asco.org/.
The following QUADRAMET abstracts will be presented at the SNM annual meeting:
-- "Early response and toxicity of 153Sm-EDTMP combined with docetaxel in patients with hormone-refractory metastatic prostate cancer" will be presented on Monday, June 5 from 12:30 p.m. to 12:42 p.m. during an Oral Scientific Paper Session on Oncology - Therapy: Radionuclide Therapy: General (Abstract # 297). -- "Simvastatin therapy enhances therapeutic efficacy of samarium-153- EDTMP in prostate cancer patients with multiple bone metastases" will be presented on Monday, June 5 from 12:30 p.m. to 2:00 p.m. during an Oral Scientific Paper Session on Oncology - Therapy: Radionuclide Therapy: General (Abstract # 298). -- "The use of local injection of 153Samarium-EDTMP in conjunction with kyphoplasty for palliation bone metastasis" will be presented on Tuesday, June 6 from 5:15 p.m. to 6:00 p.m. during a Scientific Poster Session on Oncology - Therapy Posters (Abstract # 1794). -- "Bone marrow scan to assess functional reserve and predict severity and duration of neutropenia and thrombocytopenia following Samarium- 153 therapy" will be presented on Tuesday, June 6 from 4:30 p.m. to 5:15 p.m. during a Scientific Poster Session on Oncology - Therapy Posters (Abstract # 1795).
The following PROSTASCINT abstracts will be presented at the SNM annual meeting:
-- "Improved disease detection with fusion of PROSTASCINT scans and multidetector CT" will be presented on Sunday, June 4 from 6:45 p.m. to 7:30 p.m. during a Scientific Poster Session on Educational Exhibits - Oncology Posters General (Abstract # 1040). -- "Retrospective diagnostic analysis of localized prostate cancer comparing needle core biopsy results to PROSTASCINT/SPECT fused with CT" will be presented on Tuesday, June 6 from 4:30 p.m. to 5:15 p.m. during a Scientific Poster Session on Oncology - Clinical Diagnosis Posters (Abstract # 1699). -- "Unusual prostate metastasis to the brain: PROSTASCINT, CT, and MRI findings" will be presented on Sunday, June 4 from 6:45 p.m. to 7:30 p.m. during a Scientific Poster Session on Educational Exhibits - Oncology Posters General (Abstract # 1052).
For more information about the SNM annual meeting, please refer to the conference website at http://www.snm.org/.
The following QUADRAMET abstract will be presented at the EHA meeting:
-- "Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma" will be presented on Saturday, June 17 during a Poster Session on Myeloma and Other Gammopathies.
For more information about the EHA meeting, please refer to the conference website at http://www.ehaweb.org/.
NOTE:
QUADRAMET is indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. This press release describes clinical applications that differ from that reported in the QUADRAMET package insert.
PROSTASCINT is indicated as a diagnostic imaging agent in newly diagnosed patients with biopsy-proven prostate cancer, thought to be clinically localized after standard diagnostic evaluation and who are thought to be at high risk for pelvic lymph node metastases. PROSTASCINT is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease. This press release describes clinical applications and imaging performance that differs from that reported in the PROSTASCINT package insert.
A copy of the full prescribing information for QUADRAMET and PROSTASCINT may be obtained in the U.S. from Cytogen Corporation by calling toll-free 800- 833-3533 or by visiting the web site at http://www.cytogen.com, which is not part of this press release.
ABOUT CYTOGEN CORPORATION
Founded in 1980, Cytogen Corporation of Princeton, NJ is a biopharmaceutical company dedicated to improving the lives of patients with cancer by acquiring, developing and commercializing innovative molecules targeting the sites and stages of cancer progression. Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide, and SOLTAMOX(TM) (tamoxifen citrate, oral solution 10mg/5mL) in the United States. Cytogen's development pipeline consists of CYT-500, a therapeutic radiolabeled antibody targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Cytogen also has exclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Full prescribing information for the Company's products is available at http://www.cytogen.com or by calling 800-833-3533. For more information, please visit the Company's website at http://www.cytogen.com, which is not part of this press release.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. There are a number of important factors that could cause Cytogen's results to differ materially from those indicated by such forward-looking statements. In particular, Cytogen's business is subject to a number of significant risks, which include, but are not limited to: the risk of obtaining the necessary regulatory approvals; the risk of whether products result from development activities; the risk of shifts in the regulatory environment affecting sales of Cytogen's products such as third-party payor reimbursement issues; the risk associated with Cytogen's dependence on its partners for development of certain projects, as well as other factors expressed from time to time in Cytogen's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Cytogen's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Cytogen undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Cytogen CorporationCONTACT: Media/Investors contact: Brian Korb, The Trout Group,+1-212-477-9007 x16, for Cytogen Corporation